The estimated Net Worth of Chris Nolet is at least $408 millier dollars as of 12 January 2023. Mr. Nolet owns over 36,497 units of Viela Bio stock worth over $360 and over the last 5 years he sold VIE stock worth over $0. In addition, he makes $407,957 as Independent Director at Viela Bio.
Chris has made over 1 trades of the Viela Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 36,497 units of VIE stock worth $912 on 12 January 2023.
The largest trade he's ever made was exercising 36,497 units of Viela Bio stock on 12 January 2023 worth over $912. On average, Chris trades about 2,807 units every 0 days since 2019. As of 12 January 2023 he still owns at least 14,403 units of Viela Bio stock.
You can see the complete history of Mr. Nolet stock trades at the bottom of the page.
Chris Nolet CPA serves as Independent Director of the Company. From 2002 to June 2019, Mr. Nolet was the West Region Life Sciences Industry Leader & Partner at Ernst & Young (EY) and has more than 38 years of experience in the profession. In addition to serving a wide array of clients, his responsibilities included leading West Region EY Life Sciences Industry Group, and serving as a member of the Global EY Life Sciences Executive Leadership Group, which established policies and operating strategies for EY Life Sciences practice worldwide. He currently serves on both the Executive Committee and Finance Committee (Co-Chair) of the California Life Sciences Industry Association, the board of directors of Revance Therapeutics, Inc., a biotechnology company, and is a former member of the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization. Prior to joining EY, Mr. Nolet was a partner at PricewaterhouseCoopers where he led the Life Sciences practice in the western U.S. Mr. Nolet has a B.S. in Accounting from San Diego State University and is a Certified Public Accountant in California.
As the Independent Director of Viela Bio, the total compensation of Chris Nolet at Viela Bio is $407,957. There are 4 executives at Viela Bio getting paid more, with Zhengbin Yao having the highest compensation of $2,747,550.
Chris Nolet is 63, he's been the Independent Director of Viela Bio since 2019. There are no older and 11 younger executives at Viela Bio.
Chris's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, 20TH FLOOR, NASHVILLE, TN, 37203.
Over the last 5 years, insiders at Viela Bio have traded over $58,712,400 worth of Viela Bio stock and bought 1,261,091 units worth $24,062,867 . The most active insiders traders include Andreas Wicki, Xiaomeng Tong et Plc Astra Zeneca Uk Ltd Ast.... On average, Viela Bio executives and independent directors trade stock every 41 days with the average trade being worth of $6,348. The most recent stock trade was executed by Aaron Ren on 18 November 2020, trading 2,000 units of VIE stock currently worth $5,680.
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Viela Bio executives and other stock owners filed with the SEC include: